Cigna Q4 Earnings Beat Estimates on Higher Specialty Volumes

Core Insights - Cigna Group reported fourth-quarter 2025 adjusted EPS of $8.08, exceeding estimates by 2.7% and reflecting a 22% year-over-year increase [1][9] - Adjusted revenues reached $72.5 billion, a 10% year-over-year rise, surpassing consensus estimates by 3.7% [1][9] Financial Performance - The Evernorth Health Services segment significantly contributed to quarterly results, driven by new business and client relationship expansion, alongside strong performance in Pharmacy Benefit Services and improved specialty volumes [2][5] - Cigna's medical customer base stood at 18.1 million, a decline of 5.4% year-over-year, impacted by divestitures to Health Care Services Corporation (HCSC) [3] - Total benefits and expenses increased by 10% year-over-year to $70.1 billion, primarily due to higher pharmacy and service costs [4] - Adjusted income from operations was $2.1 billion, up 16% year-over-year, benefiting from improved contributions from Cigna Healthcare and Evernorth Health Services [4] Segment Performance - Evernorth Health Services recorded revenues of $63.1 billion, a 17% year-over-year increase, exceeding estimates of $59.2 billion [5] - Cigna Healthcare's revenues fell 16% year-over-year to $11.1 billion, although it beat estimates by 2.1% [6] - Adjusted operating income for Cigna Healthcare surged 44% year-over-year to $734 million, despite missing consensus estimates by 2.7% [7] Financial Position - As of December 31, 2025, Cigna had cash and cash equivalents of $7.7 billion, a 1.7% increase from the previous year [8] - Total assets rose to $157.9 billion from $155.9 billion at the end of 2024 [8] - Long-term debt increased by 6.7% to $30.9 billion, while total equity grew by 1.5% to $41.9 billion [10] Capital Deployment - Cigna repurchased shares worth approximately $3.6 billion in 2025 [11] 2026 Outlook - Adjusted EPS is projected to be at least $30.25, indicating a minimum growth of 1.4% from 2025 [12] - Adjusted revenues are expected to reach around $280 billion, reflecting a 1.9% improvement from 2025 [13] - The adjusted SG&A expense ratio is estimated to be around 5% [13]